SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-015913
Filing Date
2024-02-15
Accepted
2024-02-15 16:22:04
Documents
14
Period of Report
2024-02-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prld-20240215.htm   iXBRL 8-K 50849
2 EX-99.1 prld-ex99_1.htm EX-99.1 162808
3 GRAPHIC img268059179_0.jpg GRAPHIC 5700
  Complete submission text file 0000950170-24-015913.txt   383700

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20240215.xsd EX-101.SCH 50049
15 EXTRACTED XBRL INSTANCE DOCUMENT prld-20240215_htm.xml XML 6001
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 24644126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)